Actavis' acquisition of Allergan gets EU nod
17 March 2015 | News | By BioSpectrum Bureau
Actavis' acquisition of Allergan gets EU nod
The company has purchased Allergan for $66 billion
Actavis has announced that the company has received clearance from the European Commission for its pending acquisition of Allergan.
Clearance by the European Commission satisfies the final regulatory condition to the closing of the pending acquisition, which remains subject to certain customary closing conditions and is expected to be effective on or around March 17, 2015.
Actavis has acquired Allergan for $66 billion.
